Sanofi signs drug formulation deal with OctoPlus

Updated on 14 January 2013

OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals.

sanofi-octoplus-sign-drug-formulation-deal

Sanofi, OctoPlus sign drug formulation deal

Singapore: Pharma giant, Sanofi has collaborated with OctoPlus, an advanced drug formulation and clinical scale manufacturing services provider, in formulation development.

Mr Jan Egberts, CEO of OctoPlus said, "We are proud of the confidence Sanofi has shown in our organization by signing this agreement. It reflects the success of our scientists and engineers who continuously develop new formulations and formulation processes, thereby strongly adding to the value of our clients' products."

Leave a Reply

Notify me of follow-up comments via e-mail address

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X